Paul D. Robbins and Senolytics
Robbins's reported coauthorship of navitoclax and fisetin studies connects him to senolytics research, but the available dossier lacks the details needed to assess his specific contribution or potential benefits for humans.
Paul D. Robbins and senolytics
The available dossier lists Paul D. Robbins, a professor at the University of Minnesota, as a coauthor of studies on two compounds, navitoclax and fisetin. His laboratory develops approaches that target cellular senescence and other hallmarks of aging.
This research area includes senolytics, interventions intended to selectively eliminate senescent cells, meaning cells showing signs of cellular senescence, while sparing non-senescent cells. The dossier does not provide titles, experimental details, or results for the navitoclax and fisetin studies. Coauthorship establishes Robbins's involvement in this research area, but assessing his specific contribution and any potential benefit for humans requires details from the studies themselves.
Read next: Paul D. Robbins and senolytics
This connection has a concrete basis in named compounds and explains both Robbins's research focus and the evidence still needed to assess his work.